| Date Filed | Type | Description |
| 08/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/11/2023 |
4
| Thye Dirk (CEO) has filed a Form 4 on Quince Therapeutics, Inc.|
Txns:
| Bought 88,000 shares
@ $1.26, valued at
$110.9k
|
|
| 08/10/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/09/2023 |
4
| Thye Dirk (CEO) has filed a Form 4 on Quince Therapeutics, Inc.|
Txns:
| Bought 80,000 shares
@ $1.24, valued at
$99.2k
|
|
| 08/09/2023 |
4
| Hannah Brendan (Chief Business Officer) has filed a Form 4 on Quince Therapeutics, Inc.|
Txns:
| Bought 71,762 shares
@ $1.22, valued at
$87.5k
|
|
| 08/09/2023 |
4
| McLoughlin Margaret (Director) has filed a Form 4 on Quince Therapeutics, Inc.|
Txns:
| Bought 8,000 shares
@ $1.23, valued at
$9.8k
|
|
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/24/2023 |
8-K
| Quarterly results |
| 07/17/2023 |
SC 13G
| BML Investment Partners, L.P. reports a 5.1% stake in Quince Therapeutics, Inc. |
| 05/26/2023 |
4
| Senner Christopher J. (Director) has filed a Form 4 on Quince Therapeutics, Inc.|
Txns:
| Granted 27,000 options to buy
@ $1.58, valued at
$42.7k
|
|
| 05/26/2023 |
4
| RYAN UNA S (Director) has filed a Form 4 on Quince Therapeutics, Inc.|
Txns:
| Granted 27,000 options to buy
@ $1.58, valued at
$42.7k
|
|
| 05/26/2023 |
4
| McLoughlin Margaret (Director) has filed a Form 4 on Quince Therapeutics, Inc.|
Txns:
| Granted 27,000 options to buy
@ $1.58, valued at
$42.7k
|
|
| 05/26/2023 |
4
| Lamond David (Director) has filed a Form 4 on Quince Therapeutics, Inc.|
Txns:
| Granted 27,000 options to buy
@ $1.58, valued at
$42.7k
|
|
| 05/26/2023 |
4
| Bray June (Director) has filed a Form 4 on Quince Therapeutics, Inc.|
Txns:
| Granted 27,000 options to buy
@ $1.58, valued at
$42.7k
|
|
| 05/25/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 04/14/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/14/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/14/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/05/2023 |
8-A12B
| Form 8-A12B - Registration of securities [Section 12(b)]: |
| 04/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I... |
| 04/04/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/31/2023 |
SC 13G
| TANG CAPITAL PARTNERS LP reports a 10% stake in Quince Therapeutics, Inc. |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/15/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/15/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/06/2023 |
4
| Monohon Ted (Chief Accounting Officer & VP) has filed a Form 4 on Quince Therapeutics, Inc.|
Txns:
| Sold 1,871 shares
@ $0.98, valued at
$1.8k
|
|
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/30/2023 |
8-K
| Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Other Events &nbs... |
| 01/27/2023 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 12/16/2022 |
8-K
| Quarterly results |
|